New immune drug shows promise in early cancer trial
NCT ID NCT04397276
First seen Nov 01, 2025 · Last updated Jun 02, 2026 · Updated 35 times
Summary
This early-phase study tested an experimental drug called JNJ-70218902 in 82 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by redirecting the body's T cells to attack cancer cells. The main goals were to find the safest dose and to monitor side effects. This is a first step in understanding whether the drug might help control advanced cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEOPLASMS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
BC Cancer Agency - Vancouver BC
Vancouver, British Columbia, V5Z 4E6, Canada
-
Hosp Univ Fund Jimenez Diaz
Madrid, 28040, Spain
-
Hosp Univ Hm Sanchinarro
Madrid, 28050, Spain
-
Hosp Univ Vall D Hebron
Barcelona, 08035, Spain
-
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9, Canada
-
Rambam Medical Center
Haifa, 31096, Israel
-
Sourasky Medical Center
Tel Aviv, 64239, Israel
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.